This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study (preprint)
medrxiv; 2022.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2022.05.31.22275010
ABSTRACT
Background:
Ongoing outbreaks of COVID-19 have been associated with waning immunity following primary immunizations and emergence of new SARS-CoV-2 variants. Heterologous boosters have been suggested to maintain population immunity.Methods:
In this study of heterologous boosters we assessed immunogenicity and reactogenicity of booster doses of different formulations of alum-adjuvanted SCB-2019 vaccine (9 g SCB-2019 with or without CpG-1018 adjuvant, or 30 g SCB-2019 with CpG-1018) in Brazilian adults primed with ChAdOx1-S vector vaccine. S-protein and ACE2 binding antibodies were measured by ELISA on Days 1, 15 and 29. Participants self-reported solicited adverse events and reactions.Results:
All SCB-2019 formulations increased ELISA antibodies against S-protein and ACE2 to a greater extent than ChAdOx1-S. After 30 g SCB-2019+CpG+alum titers against wild-type S-protein and ACE2 were significantly higher than after ChAdOx1-S on Days 15 and 29, as were GMTs for neutralizing antibodies against wild-type strain and Beta, Gamma, Delta, and Omicron variants. Boosting with SCB-2019 or ChAdOx1-S was well tolerated with no vaccine-related serious or severe adverse events.Conclusions:
Heterologous boosting with SCB-2019 of ChAdOx1-S-primed adults was more efficient in increasing immunity against wild-type strain and SARS-CoV-2 variants than a homologous ChAdOx1-S booster, highest responses being with the 30 g SCB-2019+CpG+alum formulation.
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS